EUCTR2009-015556-15-LV进行中（未招募）不适用
A Multicenter, Randomized, Open-Label, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon ß 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis - SURPASS
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Have signed written informed consent (in person or through guardian) to participate in the study and provided written authorization to use protected health information in accordance with local laws.
- •2. Have a diagnosis of relapsing remitting multiple sclerosis as defined by the revised McDonald Committee criteria (Polman 2005).
- •3. Must have been treated with a stable regimen of either glatiramer acetate (20 mg per day SC) or interferon ß-1a (44 mcg 3 times per week) as their principal first therapy for MS for 6 to 25 months prior to screening. (Note: prior treatment with another MS therapy of =30 days total duration is not exclusionary [e.g., titration to 44 mcg is allowed]).
- •4. Have shown evidence of disease activity within 12 months prior to screening while on therapy. Disease activity must be observed after a minimum of 6 months of treatment, but before 25 months of treatment. Disease activity is defined as:
- •One or more clinical relapses (Relapses must occur after 6 months of treatment, but before 25 months of treatment)
- •Two or more new MRI lesions (Gd+ and/or T2 hyperintense) observed on an MRI scan. Qualifying lesions must be observed on scans performed after 6 months of treatment, but before 25 months of treatment. These qualifying scans must support at least one of the following:
- •a. =2 Gd+ lesions on MRI scan(s)
- •b. =2 new T2 hyperintense lesions observed on an MRI scan when compared with a *baseline MRI scan
- •c. =1 Gd+ lesion and =1 new T2 hyperintense lesion observed on an MRI scan when compared with a *baseline MRI scan
- •* A baseline MRI scan is an MRI scan performed at the initiation of therapy (±6 weeks) that is compared with subsequent MRI scans to determine if new T2 hyperintense lesions are observed. If this baseline scan at initiation of therapy is not available, any scan performed after initiation of therapy may be used as the baseline MRI. New T2 MRI activity must be verified by the central reader center.
- •5. Be naïve to natalizumab.
- •6. Be between the ages of 18 and 60, inclusive at the time of informed consent.
- •7. Have a documented EDSS score between 0.0 and 5.5, inclusive.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 76
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Patients with these conditions may also have superimposed relapses, but are distinguished from relapsing-remitting patients by the lack of clinically stable periods or clinical improvement.
- •2. Have known intolerance, contraindication to, or history of non-compliance with, the use of glatiramer acetate or interferon ß-1a.
- •3. Have had an MS exacerbation (relapse) within 30 days prior to randomization AND/OR the patient has not stabilized from a previous relapse, in the opinion of the Investigator, prior to randomization.
- •4. The patient is considered by the Investigator to be immunocompromised based on medical history, physical examination, laboratory testing, or due to prior immunosuppressive or immunomodulating treatment.
- •5. Subjects for whom MRI is contraindicated, i.e., have pacemakers or other contraindicated implanted metal devices, have suffered or are at risk for side effects from gadolinium (Gd), or have claustrophobia that cannot be medically managed.
- •6. History of any clinically significant (as determined by the Investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease that would preclude participation in a clinical trial.
- •7. History of malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured).
- •8. Known history of Human Immunodeficiency Virus (HIV).
- •9. Positive test result for Hepatitis C virus (test for hepatitis C virus antibody [HCV Ab]) or hepatitis B virus (test for hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody [HBcAb]).
- •10. History of transplantation or any anti-rejection therapy.
- •11. History of severe allergic or anaphylactic reactions or known drug hypersensitivity.
- •12. A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to screening.
- •13. History of PML.
- •14. Prior treatment with total lymphoid irradiation, cladribine, mitoxantrone, fingolimod, T-cell or T-cell receptor vaccination, cyclophosphamide, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, or any therapeutic monoclonal antibody, including natalizumab or rituximab.
- •15. Prior treatment with intravenous immunoglobulin (IVIg), plasmapheresis or cytapheresis within 6-months prior to randomization.
- •16. Treatment with IV or oral corticosteroids within 30 days of randomization.
- •17. Treatment with 4-aminopyridine for subjects in countries where marketing authorization has not been obtained. Treatment with compounded formulations of 4-aminopyridine is prohibited for all subjects.
- •18. Treatment with an approved formulation of 4-aminopyridine (i.e., fampridine-SR,
- •dalfampridine, or Ampyra) for =90 days prior to randomization in countries where marketing authorization has been obtained.
- •19. Female subjects considering becoming pregnant while in the study.
- •20. Female subjects of childbearing potential who have a positive pregnancy test at either the Screening Visit or the Day 0 (Baseline) Visit.
- •21. Female subjects who are pregnant or currently b
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)The myelodysplastic syndromes (MDS) are a group of potentially acute myeloid leukemic disorders. The disorders of myeloid origin include acute myeloid leukemia (AML), MDS and myeloproliferative disorders such as chronic myeloid leukemia.MedDRA version: 6.1Level: PTClassification code 10028533EUCTR2004-001507-35-HUPharmion Corporation354
进行中（未招募）
1 期
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid ArthritisMedDRA version: 18.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-004339-21-PLsanofi-aventis Recherche & Développement200
进行中（未招募）
不适用
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisEUCTR2009-015556-15-CZBiogen Idec Limited76
进行中（未招募）
1 期
A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)The myelodysplastic syndromes (MDS) are a group of potentially acute myeloid leukemic disorders. The disorders of myeloid origin include acute myeloid leukemia (AML), MDS and myeloproliferative disorders such as chronic myeloid leukemia.MedDRA version: 6.1Level: PTClassification code 10028533EUCTR2004-001507-35-CZPharmion Corporation32
已完成
3 期
Study to assess Efficacy and Safety of Combination Tablet of Dapagliflozin, Sitagliptin and Metformin Hydrochloride Tablets in Comparison to Combination Tablet of Sitagliptin and Metformin Hydrochloride in Patients With Type 2 Diabetes MellitusCTRI/2022/04/041817Sun Pharma Laboratories Limited270